Medical Areas


Malcisbo is specialized on glycoengineering technologies and recombinantly producing carbohydrate structures to be used as novel and efficient glycoconjugate vaccines to elicit anti - bacterial immune response. Our platform technology to express specific sugar moieties recombinantly on vector bacteria can be applied for a variety of bacterial diseases and provides a tool for the development of cost-efficient vaccines.

First products

Our first vaccine targets human food poisoning caused by Campylobacter bacteria. Campylobacter jejuni is a normal gut bacterium of chicken and is the major source of food poisoning in humans through contamination of chicken meat. The vaccine is aiming at the reduction of Campylobacter bacteria in the gut of chickens thereby reducing human exposure and disease.

With this project Malcisbo has started in February 2016 a collaboration with a large pharma company.

The second vaccine targets Actinobacillus pleuropneumoniae (APP) in pigs.  APP is causing pneumonia often leading to death and major economic losses in the pig production industry.

Further applications

Apart from bacterial diseases, Malcisbo`s glycoengineering technologies can be used for the development of vaccines against other pathogens, such as parasites. Malcisbo has started a project on Dirofilaria immitis, the canine heartworm, the commercially most important nematode parasite in veterinary medicine. In this context we participate in a European project (Marie Curie Program, GlycoPar).

Latest News

  • 25 January 2017

    Malcisbo has been selected as emerging company to present at the Animal Health Investment Forum in London (Feb 2017)

  • 21 December 2016

    Malcisbo participates in a CTI-funded research project on the development of a vaccine against APP.

  • 29 February 2016

    Collaboration with a pharma company

    R&D collaboration with a pharma company targeting our Campylobacter vaccine.